skip to Main Content
Former Big Pharma Exec Makes the Switch From OxyContin to Marijuana

John Stewart used to run the pharmaceutical company behind the narcotic painkiller OxyContin. Now he is banking on medical marijuana.

Mr Stewart does not know which is more controversial these days, OxyContin or pot.

He guesses the average person would give “a bigger negative” to the powerful and controversial painkiller that has been linked to the opioid overdose and addiction epidemic in the US and Canada.

“There is a lot of anti-opioid sentiment,” he says, delicately. “And certainly based on the social disruption that we’ve seen it’s understandable.”

In the US, an estimated 1.9 million Americans were addicted to prescription opioid painkillers in 2014. Accidental overdoses from prescription painkillers quadrupled between 1999 and 2012. In 2014, drug overdoses were the leading accidental cause of death south of the border, driven by prescription opioids. [Read more at BBC]

This Post Has One Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Stories

Hawaii Senate Kills ‘De Facto’ Weed Legalization

A bill to increase the amount of marijuana a person can possess before facing stiff criminal penalties failed 15-9 in the Hawaii Senate on Monday. It was the second defeat…

Kentucky’s Medical Cannabis Program Undergoes Dramatic Transformation: Navigating HB 829 and the Emergency Licensing Regulations

By Hannah King and Arin Aragona Plans for Kentucky’s medical cannabis program took a significant turn last week with the passage of House Bill 829 and the implementation of emergency…

Cannabis in Court: When Federal Courts Will Hear Commercial Disputes Related to the Cannabis Business

By Steven Ascher and Anna M.Windemuth The unique status of the cannabis business —  legal in a majority of states, but still illegal under federal law — creates a thorny…

Patchwork Regulation of CBD Products Continues Despite Rise in Demand

By Courtney A. Hunter and Jessalyn H. Zeigler Demand for cannabidiol (CBD) products continues to climb, and the market has risen to the occasion. There is now a robust array…

More Categories

Back To Top
×Close search
Search